Bouck Noël
Dept of Microbiology-Immunology and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 310 East Superior Street, Chicago, Il 60611, USA.
Trends Mol Med. 2002 Jul;8(7):330-4. doi: 10.1016/s1471-4914(02)02362-6.
Sight-threatening eye diseases can be caused and exacerbated by the aberrant growth of new blood vessels. Recent work indicates that this neovascularization not only is a response to a rise in the local concentration of molecules that induce such angiogenesis but also requires a fall in the levels of endogenous molecules that inhibit angiogenesis. One of the most potent of these endogenous inhibitors is pigment epithelium-derived factor (PEDF), which serves as a survival factor for neuronal components of the eye as well as an essential inhibitor of the growth of ocular blood vessels. Its anti-angiogenic activity is selective in that it is effective against newly forming vessels but spares existing ones, and it is reversible. The molecular basis for this delicate control of endothelial cells is beginning to be understood and strategies to test the ability of PEDF to ameliorate or prevent vessel damage in the eye are developing rapidly.
威胁视力的眼部疾病可能由新生血管的异常生长引起并加剧。最近的研究表明,这种新生血管形成不仅是对诱导血管生成的分子局部浓度升高的一种反应,而且还需要内源性血管生成抑制分子水平的下降。这些内源性抑制剂中最有效的一种是色素上皮衍生因子(PEDF),它既是眼部神经元成分的存活因子,也是眼部血管生长的重要抑制剂。其抗血管生成活性具有选择性,即它对新形成的血管有效,但对现有血管无影响,并且是可逆的。这种对内皮细胞的精细控制的分子基础正开始被理解,并且测试PEDF改善或预防眼部血管损伤能力的策略正在迅速发展。